AU2001261466A1 - Therapeutic approaches to diseases by suppression of the nurr subfamily of nuclear transcription factors - Google Patents

Therapeutic approaches to diseases by suppression of the nurr subfamily of nuclear transcription factors

Info

Publication number
AU2001261466A1
AU2001261466A1 AU2001261466A AU6146601A AU2001261466A1 AU 2001261466 A1 AU2001261466 A1 AU 2001261466A1 AU 2001261466 A AU2001261466 A AU 2001261466A AU 6146601 A AU6146601 A AU 6146601A AU 2001261466 A1 AU2001261466 A1 AU 2001261466A1
Authority
AU
Australia
Prior art keywords
seq
crh
expression
arthritis
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001261466A
Other languages
English (en)
Inventor
Barry Bresihan
Orla M. Conneely
Oliver Fitzgerald
Evelyn Murphy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Original Assignee
Baylor College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College of Medicine filed Critical Baylor College of Medicine
Publication of AU2001261466A1 publication Critical patent/AU2001261466A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
AU2001261466A 2000-05-12 2001-05-11 Therapeutic approaches to diseases by suppression of the nurr subfamily of nuclear transcription factors Abandoned AU2001261466A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20364500P 2000-05-12 2000-05-12
US60203645 2000-05-12
PCT/US2001/015311 WO2001087923A1 (fr) 2000-05-12 2001-05-11 Approches therapeutiques de maladies par suppression de la sous-famille nurr des facteurs de transcription nucleaires

Publications (1)

Publication Number Publication Date
AU2001261466A1 true AU2001261466A1 (en) 2001-11-26

Family

ID=22754756

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001261466A Abandoned AU2001261466A1 (en) 2000-05-12 2001-05-11 Therapeutic approaches to diseases by suppression of the nurr subfamily of nuclear transcription factors

Country Status (6)

Country Link
US (1) US20020049151A1 (fr)
EP (1) EP1287019A4 (fr)
JP (1) JP2004514649A (fr)
AU (1) AU2001261466A1 (fr)
CA (1) CA2408373A1 (fr)
WO (1) WO2001087923A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT500019B1 (de) * 2001-06-27 2007-06-15 Inst Gefaessbiologie Und Throm Verwendung in vitro des transkriptionsfaktors nak-1 oder von nak-1 regulierten genen zur diagnose von entzündlichen und malignen erkrankungen
US20030220288A1 (en) * 2002-04-17 2003-11-27 Baylor College Of Medicine Nor-1 and nur77 nuclear receptors as targets for anti-leukemia therapy
US7115373B2 (en) 2002-06-27 2006-10-03 Genox Research, Inc. Method of testing for atopic dermatitis by measuring expression of the NOR-1 gene
WO2004005509A1 (fr) * 2002-07-02 2004-01-15 Genox Research, Inc. Methode d'examen d'une maladie allergique et medicament destine au traitement de celle-ci
US20040235096A1 (en) * 2002-08-26 2004-11-25 Thomas Perlmann Method for regulating dopamine producing cells
WO2005075983A2 (fr) * 2004-02-07 2005-08-18 Bayer Healthcare Ag Agents diagnostiques et therapeutiques destines a des maladies associees a un recepteur nucleaire humain nr4a3 (nr4a3)
WO2005074969A2 (fr) * 2004-02-07 2005-08-18 Bayer Healthcare Ag Diagnostics et traitements de maladies associees au recepteur nucleaire humain nr4a1 (nr4a1)
WO2005079849A2 (fr) * 2004-02-25 2005-09-01 Zgene A/S Composes pour la traitement ameliore du cancer
US20060040298A1 (en) * 2004-08-05 2006-02-23 Azriel Schmidt Rhesus monkey NURR1 nuclear receptor
US7521207B2 (en) * 2005-03-16 2009-04-21 Merck & Co., Inc. Rhesus monkey Nur77
SG126063A1 (en) * 2005-03-24 2006-10-30 Uab Research Foundation Methods for the treatment of insulin resistance and disease states characterized by insulin resistance
WO2007124148A2 (fr) * 2006-04-21 2007-11-01 The University Of North Carolina At Chapel Hill Traitement de troubles du tissu conjonctif
WO2008130949A2 (fr) * 2007-04-16 2008-10-30 University Of Florida Research Foundation, Inc. Modulation de l'expression de nurr1 dans une cellule
WO2011127288A2 (fr) * 2010-04-07 2011-10-13 La Jolla Institute For Allergy And Immunology Méthodes et utilisations de nur77 et d'agonistes du nur77 pour moduler des macrophages et des monocytes, et traiter une inflammation, une maladie inflammatoire et une maladie cardiovasculaire

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2192754A1 (fr) * 1996-12-12 1998-06-12 Jacques Drouin Nur-re, element qui lie les dimeres de recepteurs nucleaires nur; methode d'obtention et utilisation

Also Published As

Publication number Publication date
JP2004514649A (ja) 2004-05-20
WO2001087923A1 (fr) 2001-11-22
US20020049151A1 (en) 2002-04-25
EP1287019A4 (fr) 2004-12-15
EP1287019A1 (fr) 2003-03-05
CA2408373A1 (fr) 2001-11-22

Similar Documents

Publication Publication Date Title
US6846911B2 (en) Methods and compositions for inhibiting inflammation and angiogenesis comprising a mammalian CD97 α subunit
US5556754A (en) Methods for assessing the ability of a candidate drug to suppress MHC class I expression
US6596501B2 (en) Method of diagnosing autoimmune disease
US20020049151A1 (en) Therapeutic approaches to diseases by suppression of the NURR subfamily of nuclear transcription factors
US20060088532A1 (en) Lymphatic and blood endothelial cell genes
US20110052563A1 (en) Gonadal function improving agents
JP2005500854A (ja) 自己免疫疾患に対する薬剤を同定するための、自己免疫疾患のモデルおよび方法
US6906179B2 (en) Antibody to SNIP1
US6844179B1 (en) Protein and DNA thereof
AU4563599A (en) Exons 4 and 7 encode separate transactivating and chromatin localizing domains in esx
EP1448593B1 (fr) Peptides de l'alpha-fetoproteine et leurs utilisations
JP2002517209A (ja) 子宮内膜症の診断および処置におけるプロサイモシンの使用
JP2004073182A (ja) インスリン抵抗性改善剤
US20090227501A1 (en) Agents for preventing and/or treating upper digestive tract disorders
WO2006007375A2 (fr) Utilisation de bridge-1 et activateurs et inhibiteurs de ceux-ci utilises dans le traitement du diabete insulino-dependant
US20030108951A1 (en) Use of diseases-associated gene
US20040086510A1 (en) Irap-binding protein
EP1600165A1 (fr) Utilisation medicale d'un inhibiteur de mip-3alpha et procede de criblage d'un agent protecteur d'une cellule du cerveau/nerveuse
US20060035209A1 (en) Screening method
JP2005128010A (ja) インスリン抵抗性改善剤のスクリーニング方法
JP2003279567A (ja) スクリーニング方法
Zdvada et al. Pancreatic Tissue Penetration of Amikacin, Augmentin, Piperacillin and Ofloxacin in Acute Experimental Pancreatitis
JP2005151826A (ja) Ｃ１ｑｔｎｆ５の用途
US20040185500A1 (en) Use of disease-associated gene
JP2002154986A (ja) インスリン分泌調節剤